The polysilicon maker and solar developer saw its shares suspended from trading this morning after missing the deadline to publish its annual report but has been busy with another PV project fire sale.Polysilicon
MedCity News
J.P. Morgan’s life sciences outlook for 2021
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Shares0
Source: J.P. Morgan
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector despite unprecedented business challenges. Here are a few of the highlights:
Some walking tracks on Northland s Cape Brett Peninsula off limits to protect from kauri dieback
1 Apr, 2021 07:42 PM
2 minutes to read
The Cape Brett Track to the lighthouse is a tough but rewarding walk, and now some sections have been closed on the peninsula to protect kauri from the threat of kauri dieback disease.
The Cape Brett Track to the lighthouse is a tough but rewarding walk, and now some sections have been closed on the peninsula to protect kauri from the threat of kauri dieback disease.
Northern Advocate
Some of the tracks on the iconic Cape Brett Peninsula in the Bay of Islands are off limits to the public to guard against kauri dieback.
(0)
FISHERS, IN / ACCESSWIRE / April 1, 2021 / American Acquisition Opportunity Inc. (NASDAQ:AMAOU)(the Company ) announced today that it has closed the issuance of an additional 506,002 units pursuant to the partial exercise of the underwriter s over-allotment option in connection with the company s initial public offering. The units are listed on the Nasdaq Capital Market ( Nasdaq ) under the ticker symbol AMAOU . Each unit consists of one share of the Company s Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols AMAO and AMAOW, respectively.
MedCity News
United Therapeutics notches another FDA approval for lung drug
The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition.
Shares0
United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pressure affecting the lungs in patients who have a group of rare respiratory disorders called interstitial lung diseases.
The regulatory nod is the second for the inhaled version of treprostinil, which was initially approved in 2009 as a treatment for pulmonary arterial hypertension high blood pressure in the arteries that carry blood from the heart to the lungs. Silver Spring, Maryland-based United Therapeutics also sells the drug in injectable and oral formulations. Together, the three ver